Current Report Filing (8-k)
25 April 2017 - 11:01PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
April 24, 2017
Date of Report (Date of earliest event reported)
AEVI GENOMIC MEDICINE, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
1-35112
|
98-0217544
|
(State or other jurisdiction of
incorporation or organization)
|
(Commission File Number)
|
(I.R.S. Employer
Identification No.)
|
435 Devon Park Drive, Suite 715
Wayne, Pennsylvania 19087
(Address of principal executive offices,
zip code)
(610) 254-4201
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On April 24, 2017, Isaac Blech informed
Aevi Genomic Medicine, Inc. (the “
Company
”) that he intends to retire from the Company’s Board of Directors
upon the expiration of his current term at the Company’s 2017 annual meeting of stockholders (the “
2017 Annual Meeting
”).
As a result of Mr. Blech’s planned retirement, he will not stand for election at the 2017 Annual Meeting. Mr. Blech has been
a member of the Board of Directors for almost six years. The Company thanks him for his service and commitment to the Company.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
AEVI GENOMIC MEDICINE, INC.
|
|
|
|
|
|
|
|
|
By:
|
/s/ Brian D. Piper
|
|
|
|
Name: Brian D. Piper
|
|
|
|
Title: Chief Financial Officer and Corporate Secretary
|
Date: April 25, 2017
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Oct 2023 to Oct 2024